Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

263

Participants

Timeline

Start Date

November 19, 2020

Primary Completion Date

October 4, 2024

Study Completion Date

June 30, 2025

Conditions
Clostridium Difficile Infection
Interventions
DRUG

Vancomycin

Extension of initial vancomycin regimen for the treatment of C. diff from 14 days to 28 days (i.e. an additional 14 days of vancomycin treatment)

DRUG

Placebos

Initial vancomycin treatment (x14 days) will be followed by 14 days of placebo.

Trial Locations (12)

V5Z 1M9

Vancouver General Hospital, Vancouver

A1B 3V6

Health Sciences Centre - Eastern Health, St. John's

K7L 2V7

Kingston Health Sciences Centre, Kingston

K1Y 4E9

The Ottawa Hospital, Ottawa

M4C 3E7

Michael Garron Hospital, Toronto

M4N 3M5

Sunnybrook Health Science Centre, Toronto

M5B 1W8

St. Michael's Hospital, Toronto

M5G 1L7

University Health Network, Toronto

M6R 1B5

St Joseph's Health Care, Toronto

H3T 1E2

Jewish General Hospital, Montreal

H4A3J1

McGill University Health Centre (Royal Victoria Hospital), Montreal

J1H 5N4

Centre hospitalier universitaire de Sherbrooke, Sherbrooke

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

lead

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER